The overuse of azithromycin during COVID-19 led to several issues, including increased resistance to the medication. Initially, concerns centered around QT prolongation, but a recent retrospective study published in JACC: Advances discusses additional risks associated with azithromycin exposure, including ‘long-term subsequent MI,’ ’30-day hospital readmissions,’ and ’30-day incident heart failure among MI patients.’